Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

481.24 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 305
Open 481.24
Bid (Size) 482.00 (5)
Ask (Size) 487.55 (1)
Prev. Close 481.24
Today's Range 481.24 - 481.24
52wk Range 340.83 - 510.63
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Vertex Pharmaceuticals has a lot going for it. 
Via The Motley Fool

Performance

YTD
+17.12%
+17.12%
1 Month
-2.83%
-2.83%
3 Month
+7.69%
+7.69%
6 Month
+11.02%
+11.02%
1 Year
+36.87%
+36.87%

More News

Read More
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Via Benzinga
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
Via InvestorPlace
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in August
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in August 2024
Via InvestorPlace
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Via The Motley Fool
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Via InvestorPlace
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
Via The Motley Fool
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Via The Motley Fool
3 Biotech Stocks That Could Have Investors Grinning Soon
Via InvestorPlace
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Via Benzinga
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.